MaxCyte's Innovative Collaboration with Moonlight Bio on T Cell Therapies
MaxCyte Forms Strategic Alliance with Moonlight Bio
MaxCyte, Inc. (Nasdaq: MXCT), a pioneering cell-engineering organization, has recently announced a significant collaborative effort with Moonlight Bio, a Seattle-based company focused on pioneering preclinical-stage T cell therapies. This partnership will leverage MaxCyte’s advanced technologies to propel the development of innovative T cell treatments designed specifically for solid tumors.
Technological Edge in T Cell Therapy Development
In the agreement, Moonlight Bio will utilize MaxCyte’s acclaimed Flow Electroporation technology, integrated with the ExPERT platform. These advanced tools are engineered to streamline the development and manufacturing processes of T cell therapies, enabling scalable production to meet the growing demand in the cancer treatment landscape.
“Our collaboration with Moonlight Bio represents a shared vision of advancing cutting-edge gene-edited cell therapies,” stated Maher Masoud, MaxCyte’s President and CEO. The ExPERT platform is recognized globally for its GMP-compliance and regulatory approvals, positioning it as a pivotal asset in optimizing therapeutic outcomes. By facilitating the engineering of cells at an unprecedented scale, MaxCyte’s technologies stand to make a substantial impact on the clinical efficacy of T cell treatments.
Mission-Driven Focus on Solid Tumors
Moonlight Bio is dedicated to overcoming the significant challenges that T cell therapies face, particularly in solid tumors, which are a critical area of concern in cancer treatment. “Solid tumors are notorious for their resilience against existing therapeutic solutions, noting a dire need for more potent intervention methods,” said Jordan Jarjour, Chief Scientific Officer at Moonlight Bio.
With this strategic partnership, Moonlight Bio aims to transform its T cell therapy pipeline to provide effective therapies designed to penetrate these malignant tumors, addressing a key segment of the global cancer burden. Their proactive approach to T cell therapies seeks to generate deeper and more durable responses, giving hope to patients with limited treatment options.
Key Aspects of the Strategic License
Through the Strategic Platform License agreement, Moonlight Bio has secured comprehensive research, clinical, and commercial rights to employ MaxCyte's technology for advancing their T cell therapies. In exchange, MaxCyte stands to gain annual licensing fees along with revenue tied to program developments, establishing a mutually beneficial ecosystem.
About MaxCyte
MaxCyte has long been at the forefront of cell engineering innovation, championing the mission of ‘building better cells together.’ With a commitment that spans over 25 years, MaxCyte's cutting-edge technologies aim to comment on the future of medicine through the development and commercialization of next-generation cell therapies. The Flow Electroporation technology and SeQure gene editing risk assessment services are noteworthy aspects of their offering, designed to enable precise and efficient cell engineering across diverse applications.
Backed by a team of experts providing scientific, technical, and regulatory assistance, MaxCyte empowers researchers worldwide to engineer a variety of cell types and therapeutic payloads, accelerating the path to effective treatments for human health.
Company Contacts
For more information about MaxCyte's advancements in cell engineering or their latest collaborations, you can reach their Investor Relations via:
Investor Relations:
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
Media Contact:
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
About Moonlight Bio:
Moonlight Bio is focused on developing enhanced T cell therapies aimed at providing innovative options for cancer patients. They emphasize the importance of generating therapies that can meet and exceed the existing limitations in treating solid tumors. For further inquiries, connect with Moonlight Bio via: info@moonlightbio.us.
Frequently Asked Questions
What is the purpose of the MaxCyte and Moonlight Bio collaboration?
The collaboration aims to develop advanced T cell therapies for solid tumors using MaxCyte's innovative technologies.
What technologies will Moonlight Bio be utilizing from MaxCyte?
Moonlight Bio will deploy MaxCyte’s Flow Electroporation technology and ExPERT platform for their T cell therapy pipeline.
How does this partnership benefit MaxCyte?
MaxCyte stands to gain annual licensing fees and additional program-related revenue through this strategic license agreement.
What is Moonlight Bio's mission?
Moonlight Bio is dedicated to delivering potent T cell therapies that effectively address the challenges associated with treating solid tumors.
How can I learn more about MaxCyte and its technologies?
Detailed information is available on the MaxCyte website and inquiries can be directed to their investor relations team.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.